PROPEL - 用于评估 ENPP1 和 ABCC6 缺陷的前瞻性观察患者登记
用于评估 ENPP1 缺陷和婴儿发病 ABCC6 缺陷(GACI 2 型)患者疾病进展的前瞻性观察患者登记
The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes [PROs]) of each disease during routine, standard-of-care visits, with the aim of developing a comprehensive understanding of the burden of illness and progressive nature of the disease.
研究概览
地位
详细说明
ENPP1 Deficiency is a rare, genetic disorder caused by inactivating mutations in the ENPP1 gene that encodes the ENPP1 enzyme. Infantile-onset ENPP1 Deficiency has a high mortality (approximately 50%) in the first 0 to 6 months of life, a result of downstream cardiopulmonary complications. Pediatric patients with ENPP1 Deficiency typically experience rickets, a condition also known as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adults experience osteomalacia (softened bones), and they can exhibit a range of signs and symptoms that include hearing loss, arterial calcification, and cardiac and/or neurological involvement.
Like ENPP1 Deficiency, infantile-onset ABCC6 Deficiency is a rare, genetic disorder caused by mutations in the ABCC6 gene. Infantile-onset of ABCC6 Deficiency resembles the acute infantile form of ENPP1 Deficiency. Pediatric patients with biallelic or monoallelic ABCC6 mutations can present with cerebrovascular disease.
This is an international, multicenter, prospective, non-interventional, observational registry of patients with biallelic variants in ENPP1, symptomatic patients with monoallelic ENPP1 variants and the infantile-onset form of ABCC6 Deficiency (<18 years of age). The registry will include patients with ENPP1 Deficiency or infantile-onset of ABCC6 Deficiency independent of treatment regimen. Note: patients participating in an INZ-701 interventional clinical study are not eligible.
Registry participation will consist of a Screening Period and an Observational Period. During the Screening Period, both retrospective data (past medical history) and data available at the time of consent (baseline visit) will be collected. Data collected will include standard of care assessments, which may consist of any or all of the following: laboratory testing, radiographical assessment of calcification and vascular stenosis, bone mineralization, with addition of performance outcomes, patient-, caregiver-, and physician-reported outcomes, and healthcare utilization. During the Observational Period, participants will be assessed during their routine visits for changes in their disease and PROs and data will be added periodically to the database. There will be an opportunity for an optional blood draw to assess levels of inorganic pyrophosphate (PPi) at each routine visit.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T1C5
- CHU Sainte-Justine Research Centre
-
-
-
-
-
Istanbul、土耳其(türkiye)、34764
- Umraniye Training and Research Hospital
-
-
-
-
-
Hamburg、德国、20251
- Universitätsklinikum Hamburg-Eppendorf
-
-
-
-
-
Milan、意大利、20132
- IRCCS San Raffaele Hospital - Main
-
-
-
-
-
Tokyo、日本、113-8655
- The University of Tokyo Hospital
-
-
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Ann and Robert H. Lurie Children's Hospital
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Boston Children's Hospital
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic
-
-
New Jersey
-
Eatontown、New Jersey、美国、07724
- CLINILABS Drug Development Corp
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- The Children's Hospital of Philadelphia (CHOP)
-
-
-
-
-
Derby、英国、DE11 7AQ
- VCTC
-
-
-
-
-
Barcelona、西班牙、08029
- EU Hub - VCTC
-
Barcelona、西班牙、08950
- Hospital Sant Joan de Deu
-
-
-
-
-
Muscat、阿曼
- Royal Hospital Muscat
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Evidence of biallelic ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) variants in ENPP1 Deficiency
or
Evidence of monoallelic ENPP1 variants and disease-related symptoms
or
Infantile onset with biallelic adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) variants in participants aged <18 years.
描述
Inclusion Criteria:
Individuals eligible to participate must meet all the following inclusion criteria:
-
Must provide written or electronic consent after the nature of the registry has been explained, and prior to any research-related procedures, per International Council for Harmonisation (ICH) Good Clinical Practice (GCP)
-
Agree to provide access to relevant medical records
-
One of the following genetic or clinical criteria
-
A confirmed prenatal or postnatal molecular genetic diagnosis of ENPP1 Deficiency with biallelic mutations (ie, homozygous or compound heterozygous) performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) certified laboratory or regional equivalent
OR
-
Monoallelic ENPP1 mutation confirmed by a certified CAP/CLIA laboratory or regional equivalent and any of the following clinical symptoms:
i. ≥ 1 traumatic vertebral fracture
-
ii. ≥ 2 fractures as an adult (eg, long-bones, digits, vertebrae)
iii. Low bone mineral density (dual-energy X-ray absorptiometry [DXA] Z-score <1.5) and <55 years of age
iv. Bone or joint pain interfering with movement or daily activities
v. History of myocardial infarction (MI), unstable angina, transient ischemic attack (TIA) or low cardiac output before the age of 40 yrs.
vi. History of rickets or bone deformity
vii. Diagnosis of ossification of the posterior longitudinal ligament (OPLL)
viii. Other clinical symptoms, with approval by Inozyme
OR
c. A confirmed prenatal or postnatal molecular genetic diagnosis of ABCC6 Deficiency with biallelic mutations confirmed by a certified CAP/CLIA laboratory or regional equivalent, and <18 years of age
Exclusion Criteria:
Individuals who meet the following exclusion criteria will not be eligible to participate:
-
Participant or their legally designated representative does not have the cognitive capacity to provide informed consent
-
Patients who are currently participating in an INZ-701 interventional clinical study, with the exception of expanded access programs and long-term safety follow-up studies
- Participants in interventional studies may be approached for inclusion in the registry once their involvement in the treatment period of the clinical study has been completed
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Characterization of the natural history of ENPP1 Deficiency and the infantile-onset form of ABCC6 Deficiency longitudinally
大体时间:Annually up to 10 years
|
Assessments will be collected during each subject's routine visit. The assessments will be done per local standard of care. |
Annually up to 10 years
|
|
Assessment of Patient Functional changes through a validated Patient Reported Outcomes (PROs) tool
大体时间:Annually up to 10 years
|
For each subject, patient function will be assessed using the appropriate Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires. These may include: PROMIS Cognitive Function, PROMIS Fatigue, PROMIS Pain Intensity, PROMIS Pain Interference and PROMIS Physical Function. Each questionnaire is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always). High scores indicate more of the domain being measured (eg, more fatigue, more physical function). Raw scores are converted to T-Scores based on a mean of 50 and a standard deviation of 10, allowing comparison of the sample to the general population. Parent Proxy questionnaires will be used for children aged 5 to <18 years |
Annually up to 10 years
|
|
Assessment of Health-Related Quality-of-Life (HRQoL) changes through validated Patient Reported Outcomes (PROs) tools
大体时间:Annually up to 10 years
|
For each subject, HRQoL will be assessed using the following scales: age 5 to <18 years: Pediatric QoL scales (Short Form [SF]-10, Caregiver Global Impression of Status/Severity [CaGI-S]); age ≥18 years: Adult QoL scales (Short Form [SF]-36, Patient Global Impression of Status/Severity [PGI-S]) The SF-10 is a 10-item caregiver-completed questionnaire for assessment of physical and psychosocial HRQoL in children. Each question has 5 options ranging from "Excellent" to "Poor". Higher scores are associated with better HRQoL. The SF-36 measures a broad spectrum of physical and mental health domains, including physical functioning, role limitations due to physical and emotional problems, bodily pain, general health perceptions, vitality, social functioning, and emotional well-being. The SF-36 generates scores ranging from 0-100 with higher scores associated with better HRQoL. The CaGI-S and PGI-S will be scored across a 7-point scale with lower scores associated with better HRQoL. |
Annually up to 10 years
|
|
Measurement of inorganic phosphate (PPi) levels in patients' venous blood
大体时间:Annually up to 10 years
|
For each subject, QoL will be assessed using the following scales: global clinical impression of severity (GCI-S) and, short form 10 health survey for children and short form 36 health survey for adults short form 10 health survey for children and short form 36 health survey for adults |
Annually up to 10 years
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.